Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mustang Bio Inc (MBIO)

Mustang Bio Inc (MBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,017
  • Shares Outstanding, K 47,780
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,600 K
  • EBIT $ -24 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.45
  • Most Recent Earnings $-0.04 on 11/08/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1539 +9.03%
on 12/19/24
0.2167 -22.57%
on 11/25/24
-0.0412 (-19.71%)
since 11/20/24
3-Month
0.1539 +9.03%
on 12/19/24
0.3701 -54.66%
on 10/23/24
-0.0542 (-24.41%)
since 09/20/24
52-Week
0.1281 +30.99%
on 06/10/24
1.5300 -89.03%
on 01/12/24
-1.1522 (-87.29%)
since 12/20/23

Most Recent Stories

More News
Mustang Bio Receives Positive Listing Determination from Nasdaq

MBIO : 0.1678 (+1.64%)
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MBIO : 0.1678 (+1.64%)
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

MBIO : 0.1678 (+1.64%)
Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
MBIO : 0.1678 (+1.64%)
LEGN : 34.08 (+0.18%)
JNJ : 144.47 (+0.62%)
NRIX : 19.83 (-1.05%)
Oncology Market Rising Towards $564.5B Amid Cancer Spike and Biotech Innovations

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
MBIO : 0.1678 (+1.64%)
LEGN : 34.08 (+0.18%)
JNJ : 144.47 (+0.62%)
NRIX : 19.83 (-1.05%)
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants...

MBIO : 0.1678 (+1.64%)
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European...

MBIO : 0.1678 (+1.64%)
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory...

MBIO : 0.1678 (+1.64%)
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to...

MBIO : 0.1678 (+1.64%)
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

Fred Hutch’s Dr. Mazyar Shadman to present data on Mustang’s autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic...

MBIO : 0.1678 (+1.64%)

Business Summary

Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical'stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. Mustang Bio, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 0.1831
2nd Resistance Point 0.1790
1st Resistance Point 0.1734
Last Price 0.1678
1st Support Level 0.1637
2nd Support Level 0.1596
3rd Support Level 0.1540

See More

52-Week High 1.5300
Fibonacci 61.8% 0.9945
Fibonacci 50% 0.8291
Fibonacci 38.2% 0.6636
Last Price 0.1678
52-Week Low 0.1281

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar